Literature DB >> 18039520

Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients.

Niamh F Murphy1, Christina O'Loughlin, Mark Ledwidge, Dermot McCaffrey, Kenneth McDonald.   

Abstract

BACKGROUND: Recent advances in pharmacological and pacemaker-based treatments for heart failure (HF) have brought about significant improvements in left ventricular function. AIMS: To identify the proportion of treated systolic HF patients in whom left ventricular systolic function improves and/or returns to normal.
METHODS: This was a retrospective analysis of 221 HF patients. Improvement in left ventricular function was defined as an improvement in ejection fraction (LVEF) of > or =10% on echocardiography. Return to normal was defined as an improvement of LVEF to > or =50% and a reduction in left ventricular end diastolic diameter to < or =55 mm. Changes in BNP were also recorded.
RESULTS: Improvement in LVEF was observed in 44.3% of patients and return to normal systolic function in 10.9%, only 2.3% had both a return to normal echocardiographic parameters and a BNP<100 pg/ml. A higher percentage of the improved group were on target doses of beta-blockers (p=0.004). Baseline BNP was not a predictor of improvement. There was a trend towards a reduction in HF readmissions in the improved group (p=0.07) but no difference in the risk of death or all-cause readmission.
CONCLUSION: While a substantial proportion of treated HF patients have an improvement in left ventricular function over time, only a small proportion return to normal dimensions and LVEF, underlining the permanent nature of ventricular damage in the vast majority of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039520     DOI: 10.1016/j.ejheart.2007.10.001

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  4 in total

1.  Clinical significance of discrepant mid-wall late gadolinium enhancement in patients with nonischemic dilated cardiomyopathy.

Authors:  Shoichi Ehara; Kenji Matsumoto; Ryoko Kitada; Satoshi Nishimura; Kenei Shimada; Minoru Yoshiyama
Journal:  Heart Vessels       Date:  2018-05-26       Impact factor: 2.037

2.  Genome-wide epigenetic and proteomic analysis reveals altered Notch signaling in EPC dysfunction.

Authors:  Jamie R Karcher; Brian R Hoffmann; Pengyuan Liu; Yong Liu; Mingyu Liang; Andrew S Greene
Journal:  Physiol Rep       Date:  2015-04

3.  Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study.

Authors:  Shervin Ziabakhsh-Tabary; Rozita Jalalian; Farzad Mokhtari-Esbuie; Mohammad Reza Habibi
Journal:  Iran J Med Sci       Date:  2014-03

4.  Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy.

Authors:  Carles Díez-López; Joel Salazar-Mendiguchía; Elena García-Romero; Lara Fuentes; Josep Lupón; Antoni Bayés-Genis; Nicolás Manito; Marta de Antonio; Pedro Moliner; Elisabet Zamora; Pablo Catalá-Ruiz; Miguel Caínzos-Achirica; Josep Comín-Colet; José González-Costello
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.